VivoSeq
Nephrology

Iga Nephropathy

77

Pipeline Programs↗

34

Active Trials↗

40

Companies Involved↗

IgA Nephropathy is a moderately active landscape with 77 programs across 40 companies. The most active players are Biohaven Therapeutics Ltd., Osprey Pharmaceuticals USA, Inc., Guangdong Hengrui Pharmaceutical Co., Ltd. 19 therapies are approved with 20 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

68/100

Pipeline Velocity

39/100

Mech. Concentration

16/100

Completion Rate

70/100

Attrition Rate

14/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

B

Biohaven Therapeutics Ltd.

1 program

Phase 1O

Osprey Pharmaceuticals USA, Inc.

1 program

Phase 1Guangdong Hengrui Pharmaceutical Co., Ltd logo

Guangdong Hengrui Pharmaceutical Co., Ltd

2 programs

Phase 2E

Eledon Pharmaceuticals

1 program

Phase 2Amgen logo

Amgen

1 program

Phase 2R

Rigel Pharmaceuticals

1 program

Phase 2

Pipeline

Programs by Phase

Analysis

Modality Breakdown

92%

Small molecule

87 of 95 classified programs — the dominant modality here.

8%ALL OTHERSMonoclonal antibody33%Protein / enzyme22%Cell therapy22%Peptide11%

Small molecule leads; the ring shows all 95 classified programs, each share of the total. Modality classified for 100% of 100 pipeline programs.

Analysis

Trial Status

95

clinical trials

Completed31 · 33%
Unknown status17 · 18%
Recruiting13 · 14%
Not yet recruiting12 · 13%
Active, not recruiting9 · 9%
Terminated8 · 8%
Other5 · 5%

Clinical Trials

Trial Activity

95 trials

Which of the Commonly Available and Approved Drugs in Addition to Standard of Care Can Significantly Improve the Slope of Estimated Glomerular Filtration Rate at Two Years When Compared to Standard of Care Alone in South-Asian Kidney Biopsy-proven Adult (≥18 Years) Primary IgA Nephropathy?
Recruiting·—·Phase 4·NCT06676384·585 enrolled
Open-label Extension Study of Zigakibart in Adults With IgA Nephropathy.
Recruiting·Novartis logoNovartis·Phase 3·NCT06858319·220 enrolled
A Study of SC0062 Capsule for the Treatment of IgA Nephropathy with Proteinuria
Recruiting·BBiocity Biopharmaceutics Co., Ltd.·Phase 3·NCT06819826·360 enrolled
A Trial of HRS-5965 Capsule in Primary IgA Nephropathy
Recruiting·CChengdu Suncadia Medicine Co., Ltd.·Phase 3·NCT07014826·378 enrolled
Efficacy and Safety of Extended TARPEYO® Treatment Beyond 9 Months in Adult Patients With Primary IgA Nephropathy
Recruiting·CCalliditas Therapeutics AB·Phase 4·NCT06712407·60 enrolled
Nefecon and Ambrisentan in IgA Nephropathy
Recruiting·TThe First Hospital of Jilin University·Phase 4·NCT07030894·129 enrolled
Efficacy of Immunosuppressive Therapy for IgA Nephropathy With Stage 3 or 4 CKD
Recruiting·—·Phase 3·NCT05510323·208 enrolled
A Phase IIa Clinical Study of RG002C0106 Injection in Subjects With Primary IgA Nephropathy
Recruiting·RRigerna Therapeutics Co., Ltd.; Rigerna Therapeutics (Beijing) Co., Ltd.·Phase 2·NCT07305974·30 enrolled
A Phase 2, Multicenter, Open-label Study to Evaluate the Safety and Efficacy of JADE101 in Participants With Immunoglobulin A Nephropathy (JUNIPER)
Recruiting·JJade Biosciences, Inc.·Phase 2·NCT07541287·30 enrolled
An Open-Label Biomarker Study of BHV-1400 in IgA Nephropathy
Recruiting·BBiohaven Therapeutics Ltd.·Phase 1·NCT07054684·20 enrolled
VISIONARY: Iptacopan in C3 Glomerulopathy
Recruiting·Novartis logoNovartis·Phase 3·NCT06100003·200 enrolled
APPLAUSE-IgAN: Atrasentan in IgA Nephropathy
Recruiting·Novartis logoNovartis·Phase 3·NCT04578834B·440 enrolled
SHINE-2: Iptacopan in IgA Nephropathy
Recruiting·Novartis logoNovartis·Phase 3·NCT04578834·580 enrolled
Safety and Tolerability of BION-1301 in Healthy Volunteers and Adults With IgA Nephropathy (IgAN)
Active, not recruiting·Novartis logoNovartis·Phase 1/2·NCT03945318·103 enrolled
A Study of Zigakibart in Adults With IgA Nephropathy
Active, not recruiting·Novartis logoNovartis·Phase 3·NCT05852938·383 enrolled
Page 1 of 7

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)